Kategorija: Raziskave

Posodobitev družbe Roche/ Genentech o študiji GENERATION HD2

Roche/ Genentech announce that Phase II GENERATION HD2 study is now open. This is great news for the international community since it is planned to run in 15 countries (Argentina, […]

Novartis zaključuje študijo VIBRANT-HD

Novartis shared today the difficult news that they are stopping the VIBRANT-HD study of Branaplam, after some participants devoloping side effects. Read the full Novartis letter Even if this news […]

podjetje uniQure je objavilo, da nadaljuje z vpisom bolnikov v raziskavo AMT-130 z večjim odmerkom.

A Message to the Huntington’s Disease Community from uniQure Dear Huntington’s Disease Community Members, This morning, uniQure issued a press release which included an update on our clinical trial ofAMT-130 […]

Družba Wave Life Sciences napoveduje pozitivne najnovejše podatke iz preskušanja faze 1b/2a SELECT-HD s prvimi rezultati, ki kažejo na alelno selektivno ciljno delovanje z WVE-003 pri Huntingtonovi bolezni

September 20, 2022 at 7:30 AM EDT PDF Version Single doses of WVE-003 appear generally safe and well-tolerated CSF mutant huntingtin (mHTT) protein was reduced following single doses of 30 […]

uniQure sporoča posodobitev kohorte z nizkimi odmerki v kliničnem preskušanju faze I/II genske terapije AMT-130 za zdravljenje Huntingtonove bolezni

~ Treatment generally well-tolerated with no significant safety issues related to AMT-130 in treated patients through one year of follow-up ~ ~ A mean reduction of 53.8% of mutant HTT […]

Družba Annexon Biosciences posodobi rezultate preskušanja

ANNEXON BIOSCIENCES REPORTS PHASE 2 CLINICAL TRIAL RESULTS DEMONSTRATING UPSTREAM CLASSICAL COMPLEMENT INHIBITION ASSOCIATED WITH CLINICAL BENEFIT IN HUNTINGTON’S DISEASE On June 7, Annexon, that is a clinical-stage biopharmaceutical company […]

Spletni seminar - Vse, kar morate vedeti o tehnologiji Proof-HD

Družba Prilenia je včeraj organizirala spletni seminar, na katerem je predstavila najnovejše podatke o preskušanju pridopidina v fazi III. Zahvaljujemo se vsem, ki ste se nam pridružili, in se še posebej zahvaljujemo našim govorcem, Michaelu Haydnu, Andrewu Feiginu, [...]

Prelomne novice - Roche načrtuje novo študijo Tominersena

Podjetje Roche je pravkar sporočilo nekaj spodbudnih novic. Analiza rezultatov Rochejeve raziskave faze III GENERATION HD1, ki je bila ustavljena marca 2021, je pokazala, da je [...]